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Abstract 
 
Background: IV thrombolysis (IVT) for stroke seems to be beneficial independent of the 
underlying etiology. Recent observations raised concern, that IVT might cause harm in patients 
with strokes attributable to small artery occlusion (SAO). The safety of IVT in SAO-patients is 
addressed in this study. 
Methods: We used the Swiss IVT databank to compare outcome and complications of IVT-
treated SAO-patients with IVT treated patients with other etiologies (non-SAO-patients). Main 
outcome and complication measures were functional independence after 3 months (modified 
Rankin scale 2) at 3 months, intracranial cerebral hemorrhage (ICH), and recurrent ischemic 
stroke.  
Results: Sixty-five (6.2%) of 1048 IVT-treated patients had SAO. Among SAO-patients, 1.5% 
(1/65) patients died within 3 months, compared to 11.2% (110/983) in the non-SAO-group 
(p=0.14). SAO-patients reached functional independence more often than non-SAO-patients 
(58.9% versus 75.4%; OR 2.14 (95%CI 1.20-3.81; p=0.0.01). This association became 
insignificant after adjustment for age, gender, and stroke severity (OR 1.41 95%CI 0.713–2.788; 
p=0.323). Glucose level and stroke severity but not age predicted 3-month-independence in IVT-
treated SAO-patients. ICHs (all/symptomatic) were equally frequent in SAO- (12.3%/4.6%) and 
non-SAO-patients (13.4%/5.3%;p>0.8). Fatal ICH occurred in 3.3% of the non-SAO-patients but 
were absent among SAO-patients. Recurrent ischemic stroke occurred in 1.5% of SAO-patients 
and in 2.3% of non-SAO-patients (p=0.68). 
Conclusion: IVT treated SAO-patients reached functional independence more often than IVT 
treated non-SAO-patients do. However, the variable “SAO” was a dependent rather than an 
independent outcome predictor. The absence of an excess in ICH indicates that IVT seems not to 
be harmful in SAO-patients. 
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Introduction 
IV thrombolysis (IVT) for acute ischemic stroke with recombinant tissue plasminogen activator 
has been shown safe and beneficial1. Treatment response seems to be independent of the 
underlying stroke mechanism2. However, whether this is also true for stroke attributable to small 
artery occlusion (SAO) is unclear: Theoretically, the pathogenetic mechanism of SAO-stroke may 
not be susceptible to reperfusion3. In practice, few patients in the placebo-controlled randomized 
IVT-trials had strokes due to SAO4, though this etiology accounts for up to 16% to 23% of all 
ischemic strokes5,6. Moreover, in recent case series, lacunar stroke patients treated with IVT are 
at a particular risk for early deterioration7 and seem to carry a poorer functional prognosis than 
IVT-treated patients with non-lacunar strokes8. In addition, leukoaraiosis is frequent in SAO-
patients9. As leukoaraiosis is a risk factor for symptomatic intracranial hemorrhage (ICH) after 
IVT10-12, the bleeding risk in SAO-patients may be higher than in patients with stroke etiologies 
other than SAO.(i.e., non-SAO-patients).  
With these considerations in mind, we aimed at evaluating, whether the variable “stroke etiology 
SAO” has a prognostic meaning in IVT-treated patients. Specifically, we analyzed and compared 
outcome and complications of SAO and non-SAO-patients using pooled data of Swiss stroke 
centers. 
 
Methods: 
As a joint initiative of 9 stroke centers in Switzerland, we designed a study about the significance 
of SAO as underlying stroke etiology in IVT-treated patients. All participating centers (5 university 
hospitals, 4 community hospitals) used IVT according to current guidelines13. Data were collected 
with a standardized form with predefined variables as it was also used in a previous study with 
similar methodology14. Local study participants filled in the forms systematically using 
prospectively ascertained in-hospital stroke databases or thrombolysis-registries. The completed 
forms of all centers were compiled in the coordinating center Basel, where the analyses of the 
pooled data were performed. The following variables were ascertained: Age, gender, functional 
independence prior to thrombolysis, time-to-treatment, stroke severity as assessed by the 
National Institute of Health Stroke Scale Score (NIHSS)15, etiology according to the TOAST-
criteria16, vascular risk factors according to predefined criteria, blood pressure, temperature and 
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blood glucose level obtained before IVT14. Functional outcome was assessed by outpatient visits 
or telephone calls using the modified Rankin Scale (mRS) at 3 months. Patients who died during 
follow-up were given a mRS-score of 6. Patients without any 3-month outcome information were 
excluded. All intracranial hemorrhages (ICH) were ascertained on follow-up CT or MRI obtained 
within 72 hours after IVT and additional scans in case of clinical deterioration. Applying the 
NINDS-criteria, symptomatic ICH (SICH) was defined as any CT/MRI-documented ICH temporally 
related to any deterioration in the patient’s clinical condition. Fatal hemorrhage was defined as 
any SICH leading to death. 
Each center reported on the period for which they had prospectively ascertained data on 
consecutive patients up to December 31st 2007. The appendix provides detailed data about the 
number of patients and the study period for each center. For the current study, all IVT-treated 
stroke patients were categorized according to the underlying etiology16 as SAO and non-SAO-
patients. In detail, the etiological diagnosis SAO based on the presence of a lacunar syndrome 
and neuroimaging findings comparable with a small lacunar infarction in the territory of basal or 
brainstem penetrating arteries and in the absence of steno-occlusive diseases of the parent artery 
or a cardioembolic disease16, 17. Patients with two etiologies from which one was SAO were 
excluded from the analyses.  
Main outcome measures were (i) 3-month outcome assessed as the rate of patients being 
independent (mRS 2), and those being dead, (ii) ICH (asymptomatic, symptomatic, fatal)1, and 
(iii) recurrent ischemic stroke within 3 months. 
For the subgroup of SAO-patients, predictors for a favorable outcome were sought. In detail SAO-
patients with functional independence after 3 months were compared with those being dependent 
or death with respect to baseline characteristics.  
 
Statistical analysis 
After data pooling, comparisons of SAO- and non-SAO patients were done using t- and chi-square tests. Data were given as mean and standard deviation (SD). The prognostic 
importance of the variable “SAO” was estimated by calculating odds ratios (OR) with 95% confidence intervals (95% CI) for each outcome variable (i.e., mRS2, ICH, death, recurrent 
ischemic stroke). In a second step, the OR for favorable 3-month outcome was adjusted for age14,18, gender18, and NIHSS-scores18,19 by multivariable regression analysis. Analyses were 
performed using the SPSS statistical package (SPSS for Windows, version 15.0). 
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Results 
Study population 
Among 1085 IVT-treated patients, 1048 (96.7%) fulfilled the eligibility criteria. Out of them, 65 
(6.2%) had SAO as stroke etiology, whereas 983 (93.8%) had another etiology. Both, the non-
SAO- and the SAO-patients had similar intervals to thrombolysis (153±37 versus 153±44). 
Comparing non-SAO- with SAO-patients, NIHSS score (mean 13.1±6.0 versus 9.1±4.6; median 
13 versus 8; p <0.001) and systolic blood pressure (mean 175±28 versus 155±27mmHg; <0.001) 
were significantly higher in non-SAO-patients. Smoking was more often found in SAO-patients 
(42.6% versus 23.9%, p<0.001) while coronary artery disease and atrial fibrillation was more 
common in non-SAO-patients (details see Table 1). 
In the SAO-group, 1.5% (1/65) patients died within 3 months, compared to 11.2% (110/983) in the 
non-SAO group (p=0.014). After 3 months, functional independence was reached by 75.4% 
(49/65) of the SAO patients and 58.9% (579/983) of the non-SAO patients (OR 2.14; 95%CI 1.20-
3.81; p=0.0.01). However, the correction for age, gender and NIHSS-score revealed, that the 
association between the variable “SAO as stroke etiology” and functional independence after 3 
months was no longer statistically significant (OR 1.41; 95%CI 0.713 – 2.788, p=0.323) (Table 2).  
The rates of ICH (all, symptomatic) did not differ between SAO (12.3%, 4.6%) and non-SAO-
patients (13.4%, 5.3%; (p>0.8). Fatal ICH occurred in 3.3% of the non-SAO-patients but were 
absent among SAO-patients. Recurrent ischemic events occurred in one of the SAO-patients 
(1.5% 95%CI: 0.04-8.3%) versus 23 of the non-SAO-patients (2.3%).(Table 1). 
 
SAO-patients who reached independence after 3 month differed from SAO-patients who were 
dependent or dead in lower mean glucose levels (7.1±3.2 versus 7.9±24.2, p=0.03) and a trend 
towards lower mean NIHSS-scores (8.5±4.5 versus 11.1±4.5; p=0.06). All other variables showed 
no difference between both outcome groups (Table 3). 
 
Discussion 
This study yielded the following main findings: 1) among IVT treated stroke patients, SAO-
patients had a better functional outcome than non-SAO-patients, 2) after adjustment for age, 
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NIHSS-score, and gender, “SAO” was no longer significantly associated with functional 
independence, 3) SAO-patients did not carry an ICH risk higher than that of non-SAO-patients. 
Seventy-five percent of the SAO-patients treated with IVT reached functional independence after 
3 months. Thus, taking into account the 95%CI (i.e., 63%-85%), 4 to 5 out of 6 SAO-patients can 
be expected to become functionally independent after IVT. This rate does not exceed that of 
SAO-patients in a population-based study not treated with IVT (i.e., mRS 0-2 after 3 moths was 
84.7%)6. However, population-based studies include also patients with stroke too mild to justify 
IVT. Thus, differing eligibility criteria do not allow for a one-to-one comparison with the current 
study.  
More importantly, IVT-treated SAO-patients had – unadjusted – a better outcome than IVT-
treated non-SAO-patients. The observation, that the association between functional 
independence and SAO lost statistical significance after adjustment indicates that the prognostic 
variables “age”14,18, and “stroke severity”18,19 are more important than stroke etiology being SAO. In 
addition, the adjusted point estimate of 1.41 indicates that IVT-treated SAO-patients are unlikely 
to have a worse prognosis than non-SAO-patients, despite reports about the risk of early 
neurological deterioration in IVT-treated SAO-patients7. 
In IVT-treated SAO-patients, initial glucose levels and (to some degree) stroke severities were 
associated with functional independence after 3 months. Thus, glucose20 and NIHSS-scores18,19 
as outcome predictors in IVT-treated populations of miscellaneous stroke etiologies were also 
predictive in the subgroup of SAO-patients, while age was not. 
ICH occurred rarely in IVT-treated SAO-patients. The rate of symptomatic ICH was slightly lower 
than those for all IVT-treated patients reported in the NINDS (i.e. 6.4%)1 and the ECASS-3 (i.e. 
7.9%)21 studies adhering to the same definition. 
Moreover, intracranial bleedings rates were comparable in SAO- and non-SAO-patients. The 
absence of an increased ICH risk among SAO-patients is important because leukoaraiosis as a 
risk factor for IVT-associated ICH11,22 is frequent in SAO-patients9. Thus, among IVT-treated 
patients, SAO-patients seem not to harbour an increased ICH risk.  
As a limitation, only 6% in this IVT-treated cohort had SAO as stroke etiology. This may suggest a 
selection bias, while in general a rate of 16% to 23%5,6 SAO-patients is expected. Nevertheless, 
among the 90 IVT-patients reported by Hsia et al.2 only 7 had SAO. Thus, SAO-patients seem 
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less likely to receive IVT. Potential reasons include less severe strokes and late presentation23,24. 
More importantly, we did not compare the outcome of IVT-treated SAO-patients with that of SAO-
patients not treated with IVT. Thus, the study design disallows us to answer the question, whether 
SAO-patients benefit from IVT. This question has to await the results of a randomized controlled 
trial (e.g. the IST-3 study25). However, our findings indicate a certain safety of IVT in SAO-
patients. 
In conclusion, IVT treated SAO-patients reached functional independence more often than IVT 
treated non-SAO-patients do. However, the variable “SAO” was a dependent rather than an 
independent outcome predictor. The trend towards a better outcome in SAO-patients as 
compared to non-SAO-patients and the absence of an excess in ICH suggest that IVT seems not 
to be harmful in SAO-patients. 
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Table 1 
 
Univariate analyses variables SAO-patients non-SAO-patients p value  
     
n 65 983   
     
Baseline Characteristics     
demographic data     
    Age (y)   0.40  
            median 67 69   
            mean  ± SD 65.1±13.7 66.6±13.8   
            age > 80y % (n) 11.3 (8/65) 15.5 (131/983) 0.82  
     
Male gender % (n) 
 
67.3 (43/65) 71.4 (597/983) 
 
0.39 
 
     
Vascular risk factors % (n)     
    Hypertension 54.1 (33/61) 62.0 (551/888) 0.22  
    Atrial fibrillation 0 (0/65) 19.3 (190/983) -  
    Smoking 42.6 (26/61) 23.9 (212/886) 0.001  
    Hypercholesterolemia 30.2(16/53) 34.6 (255/737) 0.50  
    Diabetes mellitus 13.1 (8/61) 14.7 (130/885) 0.74  
    Coronary heart disease 5.7 (3/53) 18.4 (148/805) 0.02  
    Prior stroke 6.7 (4/60) 7.6 (68/887) 0.78  
     
Laboratory findings prior to thrombolysis     
    Glucose level, mmol/l ± SD 7.1±3.2 7.9±24.2 0.43  
    C-reactive protein, mmol/l ± SD 5.6±6.7 10.0±21.1 0.17  
     
Blood pressure prior to thrombolysis     
    Systolic blood pressure mmHg ± SD 175±28 155±27 < 0.001  
    Diastolic blood pressure mmHg ± SD 94±17 88±18 0.020  
     
Stroke severity: NIHSS score at admission     
                         median 8 13   
                         mean ± SD 9.1±4.6 13.1±6.0 < 0.001  
     
Interval to thrombolysis (min)     
                         mean ± SD 153±44 153±37 0.97  
     
     
Outcome     
Functional outcome     
    independence, mRS 0-2  % (n) 75.4 (49/65) 58.9 (579/983) 0.009  
    death  % (n) 1.5 (1/65) 11.2 (110/983) 0.14  
     
Recurrent stroke within 90 days  % (n) 1.5 (1/65) 2.3 (23/983) 0.68  
     
Intracranial hemorrhage     
   All % (n) 12.3 (8/65) 13.4 (128/956) 0.88  
   Symptomatic+ % (n) 4.6 (3/65) 5.3 (51/956) 0.84  
         Fatal+        % (n)  0 (0/65) 3.3 (16/956) 0.30  
     
 
 
+according to the NINDS criteria1, mRS refers to modified Rankin Scale  
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Table 2: Multiple logistic regression analysis for functional independence after 3 months 
 
    
 
 
variables 
 
 
 
 
 
p-value           OR               95% CI 
 
 
 
 
 
    
NIH-Stroke Scale Score (each point) 
 <0.00
5 0.839 0.815 – 0.863 
Age (each year) 
 <0.00
5 0.966 0.955 – 0.978 
Male gender  0.902 0.980 0.707 – 1.357 
Small artery occlusion   0.323 1.410 0.713 – 2.788 
     
12 
Table 3: SAO-patients treated with IVT: predictors of functional independence after 3 months 
 
 all  
Independence 
after 3 months 
(mRS 0-2) 
Dependence/death 
after 3 months 
(mRS 3-6) 
p value
 
      
n  65 49 16   
      
demographic data      
    Age (y)      
            median   67 66 69   
            mean  ± SD 65.1±13.7 64.1 ±14.6 68.2±10.0 0.29  
            age > 80y % (n) 11.3 (8/65) 12.2 (6/49) 12.5 (2/16) 0.98  
    Male gender % (n) 67.3 (33/49) 65.3 (32/49) 68.7 (11/16) 0.80  
      
stroke severity, (median) NIHSS ± SD      
    mean 9.1±4.6 8.5±4.5 11.1±4.6 0.06  
    Median 8 7 11   
      
Laboratory findings prior to thrombolysis      
    Glucose level, mmol/l ± SD 7.1±3.2 6.6±2.3 8.6±4.7 0.033  
    C-reactive protein, mmol/l ± SD 5.6±6.7 5.2±5.6 7.1±9.6 0.55  
      
systolic arterial pressure prior to thrombolysis      
    Mean ± SD (mmHg) 175±28 172±24 182±37 0.37  
      
Interval to thrombolysis      
    (min) ± SD 153±44 154±39 149±56 0.74  
      
Antithrombotics prior to thrombolysis %  (n) 15.4 (10/65) 12.2 (6/49) 25.0 (4/16)   
      
Vascular risk factors % (n)      
    Hypertension 54.1 (33/61) 53.2 (25/47) 57.1 (8/14) 0.80  
    Atrial fibrillation 0 (0) 0 0 -  
    Smoking 42.6 (26/61) 40.4 (19/47) 50.0 (7/14) 0.53  
    Hypercholesterolemia 30.2 (16/53) 23.9 (11/46) 38.5 (5/13) 0.46  
    Diabetes mellitus 13.1 (8/61) 10.6 (5/47) 21.4 (3/14) 0.30  
    Coronary heart disease 5.7 (3/53) 7.5 (3/40) 0/13 0.32  
    Prior stroke 6.7 (4/60) 4.3 (2/46) 14.3 (2/14) 0.20  
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Participating centers (number of patients) and contributors in alphabetic order: 
Kantonsspital Aarau (105):, HJ Hungerbühler, G Schwegler 
Universitätsspital Basel (277): ST Engelter, F Fluri, F Hatz, PA Lyrer  
Inselspital Bern (35): M Arnold, HP Mattle  
CHUV Lausanne (214): P Michel, M Reichhart, M Rutgers  
HUG Geneva (73): L Sekoranja, R Sztajzel 
Kantonsspital Muensterlingen (85): F Müller 
Kantonsspital St. Gallen (24): B Weder, B Tettenborn 
Universitätsspital Zurich (USZ) (199): RW Baumgartner, D Georgiadis  
Stadtspital Zurich (Triemli) (36): R Lüthy 
 
 
 
All centers have organized stroke services and are networked in the task force ‘Stroke 
Unit & Thrombolysis’ of the Cerebrovascular Working Group of Switzerland. 
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